You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Transforming the Treatment of Hypertrophic Cardiomyopathy: Key Updates on Sarcomere-Directed Therapies

  1. In the open label extension of the REDWOOD-HCM trial of aficamten, the Kansas City Cardiomyopathy Questionnaire (KCCQ) compared baseline values with those collected at week 12 and week 24.
    Which of the following did patients experience as early as week 12?
    Symptoms remained unchanged as measured by their KCCQ scores
    Substantial symptom improvements as measured by the change in their KCCQ scores
    Worsening symptoms as measured by the change in their KCCQ scores
  2. A patient with symptomatic obstructive HCM at NYHA class II has continued obstruction despite metoprolol therapy. Echocardiography reveals left ventricular ejection fraction of 60%.
    Which is the best next step in managing this patient?
    Consider cardiac myosin inhibitor therapy
    Continue current management
    Perform follow-up echocardiography in 1 month